PEDIATRICS Vol. 96 No. 2 August 1995, pp. 320-325
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kent, J. D.
Right arrow Articles by Foley, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kent, J. D.
Right arrow Articles by Foley, C. A.

Effects of Late-Afternoon Methylphenidate Administration on Behavior and Sleep in Attention-Deficit Hyperactivity Disorder

Jeffrey D. Kent MD1, Joseph C. Blader PhD1, Harold S. Koplewicz MD1, Howard Abikoff PhD1, and Carmel A. Foley MD1

1 Division of Child and Adolescent Psychiatry, Long Island Jewish Medical Center, New Hyde Park, NY

Objective. This study evaluated the effects on behavior and sleep of methylphenidate (MPH) administered at 4 PM to children with attention-deficit hyperactivity disorder (ADHD).

Methodology. Twelve children admitted to a child psychiatric inpatient service with ADHD participated in a double-blind, crossover study in which they received a 4 PM dose of either 15 mg of MPH, 10 mg of MPH, or a placebo in random order for 12 consecutive days. Ratings of behavior, including ADHD symptoms, pertaining to the period from dose administration until sleep onset, were supplied nightly by hospital staff. Sleep latency and sleep adequacy were also assessed for each night.

Results. MPH resulted in markedly improved behavioral control compared with placebo; there was no difference between 15-mg and 10-mg MPH doses. MPH did not alter sleep latencies observed with the placebo. Children were more often rated as less tired on awakening after nights that they received 10 mg of MPH compared with 15 mg of MPH and the placebo. Weight loss was apparent among 83% of the patients, but dinner intake did not vary with third-dose condition.

Conclusions. Morning and noon administration of stimulants to children with ADHD is a near-universal practice, but many clinicians avoid a third, late-afternoon administration for fear of inducing insomnia. This study's findings show that children with ADHD derive substantial symptom reduction from MPH administered in late afternoon, with no untoward effects on sleep. Therefore, three-times-a-day dosing should be considered for those children exhibiting ADHD symptoms in the evening. Adverse effects on sleep latency were not apparent in the sample overall. Nonetheless, monitoring for possible aggravation of sleep problems and weight loss remains sound treatment practice.

Submitted on March 10, 1994
Accepted on March 6, 1995




This article has been cited by other articles:


Home page
 J Pediatr PsycholHome page
S. D. Mayes, S. L. Calhoun, E. O. Bixler, A. N. Vgontzas, F. Mahr, J. Hillwig-Garcia, B. Elamir, L. Edhere-Ekezie, and M. Parvin
ADHD Subtypes and Comorbid Anxiety, Depression, and Oppositional-Defiant Disorder: Differences in Sleep Problems
J. Pediatr. Psychol., August 1, 2008; (2008) jsn083v1.
[Abstract] [Full Text] [PDF]

Home page
 J Pediatr PsycholHome page
P. Corkum, R. Panton, S. Ironside, M. MacPherson, and T. Williams
Acute Impact of Immediate Release Methylphenidate Administered Three Times a Day on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
J. Pediatr. Psychol., May 1, 2008; 33(4): 368 - 379.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al.
Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults
Focus, October 1, 2004; 2(4): 642 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J Learn DisabilHome page
D. Stein, R. Pat-Horenczyk, S. Blank, Y. Dagan, Y. Barak, and T. P. Gumpel
Sleep Disturbances in Adolescents with Symptoms of Attention-Deficit/Hyperactivity Disorder
J Learn Disabil, May 1, 2002; 35(3): 268 - 275.
[Abstract] [PDF]

Home page
 REVIEW OF EDUCATIONAL RESEARCHHome page
N. Purdie, J. Hattie, and A. Carroll
A Review of the Research on Interventions for Attention Deficit Hyperactivity Disorder: What Works Best?
Review of Educational Research, January 1, 2002; 72(1): 61 - 99.
[Abstract] [PDF]

Home page
 PediatricsHome page
Subcommittee on Attention-Deficit/Hyperactivity Di and Committee on Quality Improvement
Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder
Pediatrics, October 1, 2001; 108(4): 1033 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
W. E. Pelham, E. M. Gnagy, L. Burrows-Maclean, A. Williams, G. A. Fabiano, S. M. Morrisey, A. M. Chronis, G. L. Forehand, C. A. Nguyen, M. T. Hoffman, et al.
Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings
Pediatrics, June 1, 2001; 107(6): e105 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
E. H. Wender
Managing Stimulant Medication for Attention-deficit/Hyperactivity Disorder
Pediatr. Rev., June 1, 2001; 22(6): 183 - 190.
[Full Text] [PDF]

Home page
 PediatricsHome page
W. E. Pelham, E. M. Gnagy, A. M. Chronis, L. Burrows-MacLean, G. A. Fabiano, A. N. Onyango, D. L. Meichenbaum, A. Williams, H. R. Aronoff, and R. L. Steiner
A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder
Pediatrics, December 1, 1999; 104(6): 1300 - 1311.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
E. J. Garland
Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats
J Psychopharmacol, January 1, 1998; 12(4): 385 - 395.
[Abstract] [PDF]